An Anti-TL1A Antibody Hit a Phase 3 Remission Endpoint in Ulcerative Colitis
Tulisokibart reportedly met a Phase 3 clinical remission endpoint in ulcerative colitis, making it a watch item for inflammatory bowel disease.
- Published
- Jun 28, 2026, 9:14 AM EDT
- Updated
- Jun 28, 2026, 10:02 AM EDT
- Reviewed
- Jun 28, 2026
- Status
- Developing
- Original source
- HCPLive
- Verification
- Corroborated reporting
- Confidence
- medium high
- Urgency
- medium
Rapid orientation
The 5-second read
- What happened
- Topline Phase 3 data are not approval, and no named patient story was surfaced.
- Why it matters
- Fresh sourceable patient-facing milestone.
- Status
- Developing
- Overclaim risk
- Medium high
- Primary source
- HCPLive (Trade news)
- Next thing to watch
- Full ATLAS-UC data, absolute remission rates, placebo comparison, maintenance study, safety, biomarker strategy, filing timeline, and payer/access implications.
Signal context
Known so far
- Condition
- Moderate-to-severe ulcerative colitis
- Intervention
- Tulisokibart anti-TL1A monoclonal antibody
- Editorial action
- Promote to published Trial Watch with medium-high overclaimRisk. Recommended status: published. Brief priority: brief-it. Signal angle: First anti-TL1A Phase 3 remission signal in UC. Strong mechanism and category signal, but no label yet. Source stack action: Use Merck as primary, Reuters/HCPLive as secondary context if needed.
Claim Check
DevelopingHCPLive reports that tulisokibart met Phase 3 endpoints in ulcerative colitis.
Safe framing
Topline Phase 3 data are not approval, and no named patient story was surfaced.
What happened
HCPLive reports that tulisokibart met Phase 3 endpoints in ulcerative colitis.
Topline Phase 3 data are not approval, and no named patient story was surfaced.
Claim boundary: Topline Phase 3 result; not approved yet.
Vital Signals
Get the weekly health signal without the wellness fog.
A clean weekly brief covering longevity science, fitness, nutrition, medicine, health culture, and the claims worth questioning.
No spam. No miracle claims. Just better health signal.
By subscribing, you agree to receive email from Viral Vitalism. Unsubscribe anytime. See our Privacy Policy.
Why it matters
- Fresh sourceable patient-facing milestone.
- Useful for separating signal from overclaim.
What not to overclaim
- Topline Phase 3 result; not approved yet.
- Do not generalize beyond the reported population.
Signal context
Context
- Primary topic
- Inflammatory Bowel Disease
- Source date
- Jun 22, 2026
- Source stack
- 3 sources
- Current status
- Developing
VV caution: Signal angle: First anti-TL1A Phase 3 remission signal in UC. Strong mechanism and category signal, but no label yet. Source stack action: Use Merck as primary, Reuters/HCPLive as secondary context if needed.
Evidence trail
Source stack
- PrimaryTrade newsJun 22, 2026HCPLive: tulisokibart Phase 3 UC endpoints
- PrimaryCompanyMerck: tulisokibart met Phase 3 primary and key secondary endpoints
- IndependentTrade newsReuters: Merck bowel disease drug meets late-stage goal
Related briefs
More brief coverage
Human Breakthrough Desk
Help us find and amplify more stories like this.
Some health stories should not vanish after one news cycle. Support the independent desk finding patient wins, medical breakthroughs, and human stories worth moving.
Support the Human Breakthrough Desk